文献速递鼻科

生物制剂治疗慢性鼻窦炎伴鼻息肉的潜在作用:一项全国性队列研究

The potential role of biological treatment of chronic rhinosinusitis with nasal polyps: a nationwide cohort study.
PubMed 文献 · Rhinology · 2021-01-01

该研究基于丹麦全国患者登记数据,纳入2012至2018年间接受首次内镜鼻窦手术的成人慢性鼻窦炎伴鼻息肉患者,评估修订手术率以估算符合生物制剂治疗标准的潜在人群。结果显示,7年内约18%的患者接受修订手术,中位时间为22个月,丹麦每年平均约120例手术患者可能从生物制剂治疗中获益。

要点

  • 丹麦成人CRSwNP首次内镜鼻窦手术 incidence 为14/100,000人年。
  • 7年内约18%患者接受修订手术,中位修订时间22个月。
  • 每年平均约120例手术患者可能符合生物制剂治疗标准。

核心结论

  • 在丹麦,每年平均120例手术患者将在7年内接受修订手术,可能受益于生物制剂作为修订手术的替代选择。

主要发现

  • CRSwNP首次内镜鼻窦手术 incidence 为14/100,000人年。
  • 约18%(每年120例)患者在7年内接受修订手术,中位修订时间为22个月。
  • 所有分析患者中21%登记有哮喘和/或过敏性鼻炎,修订手术患者中该比例为34%。

关键数值与推荐

  • 以修订手术作为生物制剂潜在适用人群的替代指标,因这些患者符合最新欧洲指南的主要标准并确保成本效益。

临床怎么用

  • 耳鼻咽喉科医生可参考修订手术率及中位时间,识别可能符合生物制剂治疗标准的CRSwNP患者。
  • 对于7年内需修订手术且合并哮喘和/或过敏性鼻炎的患者,可考虑生物制剂作为替代选项。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) can be a challenge to treat despite appropriate pharmacological therapy and endoscopic sinus surgery. With the introduction of biological treatment, costs will increase. In this study, we determine the number of patients with CRSwNP treated with endoscopic sinus surgery and revision surgery and thereby fulfil the main criterion for treatment with biologics in the newest European guidelines. Furthermore, we estimate a potential number of recipients of biologics nationwide. METHODS: All adult patients registered in the Danish National Patient Registry as having undergone first endoscopic sinus surgery for CRSwNP from 2012â€"2018 were included. The number of operations, surgery dates, and comorbidities were extracted. The Kaplan-Meier method was used to calculate the revision rate over time. Revision surgery was used as a surrogate to determine the pool of potential recipients of biologics, as these would fulfil the eligibility criteria and ensure the necessary cost-effectiveness. RESULTS: A total of 4667 operated patients with CRSwNP were included out of a population of 4.7 million adults (incidence 14/100,000 person-years). Approximately 18% (120 per year) was estimated to have revision surgery within seven years. The median time to revision surgery was 22 months. Of all analysed patients, 21% had registered asthma and/or allergic rhinitis, while these diseases were registered in 34% of patients treated with revision surgery. CONCLUSION: In Denmark, an average of 120 operated patients annually will have revision surgery within seven years and may benefit from treatment with biologics as an alternative option to revision surgery.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Eriksen PRG, Jakobsen KK, Aanæs K, et al. The potential role of biological treatment of chronic rhinosinusitis with nasal polyps: a nationwide cohort study. Rhinology. 2021. PMID: 34185823. doi:10.4193/Rhin20.480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。